中文 | EN

ASCO 2023|Presentation of Results of Five BIOKIN Pharmaceutical Clinical Studies


At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2023, BIOKIN Pharmaceutical will present the results of give important clinical studies, namely, two bi-specific Si-B001 studies, one Si-B003 study, one tetra-specific GNC-038 study and one bi-specific ADC BL-B01D1 study. The results of the BL-B01D1 study will be presented in an oral report.

BL-B01D1 is a currently exclusive bi-specific ADC drug targeting EGFR and HER3 in the clinical stage. Clinical studies in various therapeutic fields in relation to head and neck, chest, digestive tract and urinary tract have been carried out. Especially in EGFR mutation non-small cell lung cancer, it has shown amazing breakthrough effect to researchers. It has been selected to the ASCO for the first time and will be shared in the form of oral presentation.


Izalontamab (SI-B001) is a globally exclusive bi-specific antibody targeting EGFR and HER3 in the clinical stage independently, shown to be effective and well tolerated with breakthrough efficacy in multiple Phase II clinical trials. Emfizatamab (GNC-038) is the world’s first anti-tumor four-specific antibody drug in the clinical stage, shown to be effective and well tolerated in Phase I trials for the treatment of non-Hodgkin’s lymphoma and acute hematologic lymphoma. Danvilostomig (SI-B003), a bi-specific antibody targeting PD-L1 x CTLA4, is being investigated for the treatment of advanced solid tumors.


Time and form of relevant report: (Tips: The time below is Central U.S. time.)

企业微信截图_16838558901332.png  Oral Report

企业微信截图_16838559076020.pngAbstract Title

BL-B01D1, a first-in-class EGFRxHER3 bi-specific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.

Time of Report

June 5 (Monday) 8:00am-11:00am

Report Presenter

Professor Zhang Li, Sun Yat-Sen University Cancer Center

Abstract No.


企业微信截图_16838558901332.png  Poster Discussion

企业微信截图_16838559076020.pngAbstract Title

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.

 Time of Poster Display

June 4 (Sunday) 8:00am-11:00am

Time of Discussion

June 4 (Sunday) 4:30pm-6:00pm

Abstract No.


企业微信截图_16838558901332.png  Poster Display       



Baili Pharmaceutical
Guorui Pharmaceutical
Jingxi Pharmaceutical
Hiatt Technology
Company Address:1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City
Sichuan Biokin Pharmaceuticals Co.,Ltd Copyright © 2018 All rights reserved
SICPB No. 17035664-1   
Internet Drug Information Service Qualification Certificate S/N: (C)-FJYX-2022-0343